State of AI in Healthcare 2026

AI in healthcare crossed from pilot to production in 2025-2026: regulators have now cleared more than 1,450 AI-enabled medical devices and half of US healthcare organizations have deployed generative AI. The story is concentration as much as growth, with radiology accounting for roughly three-quarters of all device authorizations.

Regulatory clearances cross a milestone

The FDA authorized 1,451 AI-enabled medical devices through the end of 2025, a cumulative count that reflects how routine these approvals have become. Radiology dominates with 1,104 devices, about 76% of all authorizations, a concentration that has held remarkably steady at 73-80% across 2023 to 2025. In the fourth quarter of 2025 alone the FDA cleared 72 such devices, 55 of them in radiology. This consistency signals that imaging remains the clearest beachhead for clinical AI, where pattern recognition maps neatly onto regulatory evidence requirements.

Generative AI reaches half of providers

McKinsey's State of AI survey work shows generative AI implementation among US healthcare organizations rose from 25% in late 2023 to 47% in 2024 and 50% by the end of 2025. More than 80% of surveyed leaders report deploying at least one generative AI use case to end users. This doubling in roughly two years places healthcare among the faster-adopting sectors for the technology. The trajectory suggests provider organizations now treat generative AI as a standard operational capability rather than an experimental add-on.

A market compounding near 39% a year

Grand View Research projects the global AI-in-healthcare market will reach USD 187.7 billion by 2030, growing at a 38.5% CAGR from 2024. Software solutions led the market with a 46.3% share in 2023, while robot-assisted surgery was the largest application segment and the fastest-growing. North America captured more than 45% of the market in 2023, driven by mature health IT systems and high technology receptiveness. These figures point to a market still in steep expansion rather than approaching saturation.

Adoption outpaces measured value

The broader McKinsey data offers a cautionary frame: while 88% of organizations across industries now use AI in at least one function, only 39% attribute any EBIT impact to it, and most of those report under 5% of EBIT. Healthcare ranks among the leading sectors for AI agent experimentation, yet translating deployment into measurable clinical and financial returns remains uneven. The gap between near-universal adoption and demonstrable value is the defining challenge for healthcare AI in 2026. Closing it will depend on workflow integration and outcome evidence rather than further procurement.

FAQ

More reports

Compiled by ToolGlance from publicly reported data; figures link to their sources. Updated 2026-05-30.